Cargando…

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer

Novel strategies for the therapy of recurrent ovarian cancer are warranted. We report a study of a combinatorial approach encompassing dendritic cell (DC)-based autologous whole tumor vaccination and anti-angiogenesis therapy, followed by the adoptive transfer of autologous vaccine-primed CD3/CD28-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kandalaft, Lana E., Powell, Daniel J., Chiang, Cheryl L., Tanyi, Janos, Kim, Sarah, Bosch, Marnix, Montone, Kathy, Mick, Rosemarie, Levine, Bruce L., Torigian, Drew A., June, Carl H., Coukos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583933/ https://www.ncbi.nlm.nih.gov/pubmed/23482679 http://dx.doi.org/10.4161/onci.22664

Ejemplares similares

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
por: Kandalaft, Lana E., et al.
Publicado: (2021)

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018)

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine
por: Boudousquié, Caroline, et al.
Publicado: (2020)

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate
por: Chiang, Cheryl L-L, et al.
Publicado: (2011)

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010)

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination
por: Pasqualetti, Francesco, et al.
Publicado: (2023)

A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma
por: Matsushita, Hirokazu, et al.
Publicado: (2014)

Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma
por: Mishinov, S.V., et al.
Publicado: (2020)

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
por: Parney, Ian F, et al.
Publicado: (2022)

Autologous platelet lysate local injections for the treatment of refractory lateral epicondylitis
por: Tan, Xun-xiang, et al.
Publicado: (2016)

Characteristics of Platelet Lysate Compared to Autologous and Allogeneic Serum Eye Drops
por: Zhang, Jie, et al.
Publicado: (2020)

Super Activated Platelet Lysate, a Novel Autologous Platelet Lysate, Regulates the Expression of Inflammasome and Cytokine in the Experimental Periodontitis in Rats
por: Zhang, Yi, et al.
Publicado: (2020)

Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
por: Rojas-Sepúlveda, Daniel, et al.
Publicado: (2018)

Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes
por: Orcurto, Angela, et al.
Publicado: (2020)

The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study
por: Fea, Antonio M., et al.
Publicado: (2016)

Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
por: Belmans, Jochen, et al.
Publicado: (2017)

Human Platelet Lysate as an Alternative to Autologous Serum for Human Chondrocyte Clinical Use
por: Philippe, Virginie, et al.
Publicado: (2021)

DCVax®- DIRECT: autologous activated dendritic cells for image guided intra-tumoral vaccination in patients with solid tumors - a phase I/II clinical trial in progress
por: Subbiah, Vivek, et al.
Publicado: (2013)

Prime-Boost Vaccination with Toxoplasma Lysate Antigen, but Not with a Mixture of Recombinant Protein Antigens, Leads to Reduction of Brain Cyst Formation in BALB/c Mice
por: Wagner, Angelika, et al.
Publicado: (2015)

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
por: Bassani-Sternberg, Michal, et al.
Publicado: (2019)

Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa
por: Oboh, Mary Aigbiremo, et al.
Publicado: (2022)

Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
por: de Rosa, Francesco, et al.
Publicado: (2014)

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2021)

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2019)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s3rsio1jdgfk24vr64b2gjn776